SV

Street Verdict

Analyst Scorecard

A record of what Jefferies Analysis said publicly, with the source. Not advice.

Pending — not yet graded
“Upgraded Gland Pharma to 'Hold' from 'Underperform', raising the price target to ₹1,950 from ₹1,350. The firm believes Gland Pharma's earnings have bottomed out, with Cenexi achieving EBITDA breakeven, despite soft US performance. Full-year guidance remains strong, expecting mid-teens growth.”

Jefferies Analysis’s track record (trackable calls only): 153 graded calls · 95% CI 37–53%

Gland PharmaNeutralCalled 06 Aug 2025
Verdict:PENDING

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Read the original articleSee Jefferies Analysis’s full track record